NCT07145814

Dexmedetomidine Dose-Dependent on Lung Function and AQP1 in One-Lung Ventilation Surgery

Dexmedetomidine Dose-Dependent Modulation of Lung Function and AQP1 Expression During One-Lung Ventilation in Adults Undergoing Thoracoscopic Surgery: A Randomized Controlled Trial

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 60 (actual)
• Sponsor: People's Hospital of Guangxi Zhuang Autonomous Region · Academic / Other
• Sex: All
• Age: 40 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

This randomized controlled trial evaluated the dose-dependent effects of dexmedetomidine (DEX) on pulmonary function and aquaporin-1 (AQP1) expression during one-lung ventilation (OLV) in thoracoscopic surgery.

Conditions

• Acute Lung Injury(ALI)

Interventions

Type	Name	Description
DRUG	dexmedetomidine 0.3 µg/kg/h	Following Anesthesia induction, dexmedetomidine (DEX) Low Dose group received a DEX loading dose (0.5 µg/kg over 10 min), followed by continuous infusions of 0.3 µg/kg/h, respectively, until 30 minutes before the end of the operation.
DRUG	dexmedetomidine 0.5 µg/kg/h	Following Anesthesia induction, dexmedetomidine (DEX) high dose group received a DEX loading dose (0.5 µg/kg over 10 min), followed by continuous infusions of 0.5 µg/kg/h, respectively, until 30 minutes before the end of the operation.
DRUG	0.9 % saline	Placebo group received an equivalent volume of 0.9% saline.

Timeline

• Start date: 2018-01-05
• Primary completion: 2019-03-29
• Completion: 2019-03-29
• First posted: 2025-08-28
• Last updated: 2025-08-28

Locations

1 site across 1 country: China